<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02018991</url>
  </required_header>
  <id_info>
    <org_study_id>MUW-0001</org_study_id>
    <nct_id>NCT02018991</nct_id>
  </id_info>
  <brief_title>Late Acquired Malaposition and Different Polymers</brief_title>
  <official_title>Incidence and Predictors for Late Acquired Stent Malaposition of Drug-Eluting-Stents With Second-Generation Permanent and Biodegradable Polymer-Coatings - a Prospective, Randomized Comparison Using Optical Coherence Tomography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The polymers releasing the drug of first-generation drug-eluting stents (DES) may induce
      allergic reactions and inflammation, resulting in late-acquired stent malaposition (LASM)
      with uncoverage of struts, and risk of stent thrombosis. The incidence and predictors of LASM
      in DES with newer-generation polymers designed to improve biocompatibility are unknown.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      please see brief summary
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of stent struts with late acquired malaposition</measure>
    <time_frame>1 year after stent implantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of stent struts with late acquired malaposition</measure>
    <time_frame>2 years after stent implantation</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Late Acquired Stent Malaposition</condition>
  <arm_group>
    <arm_group_label>Everolimus-Eluting-Stent (EES)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with EES</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zotarolimus-Eluting-Stent (ZES)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with ZES</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biolimus-Eluting-Stent (BES)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients treated with BES</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Everolimus-Eluting Stent (EES)</intervention_name>
    <description>Patients treated with EES</description>
    <arm_group_label>Everolimus-Eluting-Stent (EES)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Zotarolimus-Eluting-Stent (ZES)</intervention_name>
    <description>Patients treated with ZES</description>
    <arm_group_label>Zotarolimus-Eluting-Stent (ZES)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biolimus-Eluting-Stent (BES)</intervention_name>
    <description>Patients treated with BES</description>
    <arm_group_label>Biolimus-Eluting-Stent (BES)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who underwent an elective treatment of a coronary lesion &gt; 20mm with a DES

        Exclusion Criteria:

          -  chronic renal failure (serum creatinine â‰¥ 2.5mg/dl)

          -  restenotic lesions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Neunteufl, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2013</study_first_submitted>
  <study_first_submitted_qc>December 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2013</study_first_posted>
  <last_update_submitted>December 26, 2013</last_update_submitted>
  <last_update_submitted_qc>December 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Univ. Prof. Dr. Thomas Neunteufl</investigator_full_name>
    <investigator_title>Univ. Prof. Dr.</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

